Navigation Links
PTS, Inc. erwirbt A1CNow und erweitert Produktportfolio
Date:12/23/2013

INDIANAPOLIS, 23. Dezember 2013 /PRNewswire/ -- Polymer Technology Systems, Inc. (PTS), der US-amerikanische Hersteller der CardioChek-Produktfamilie für die ambulante Diagnose, gab heute bekannt, man habe die A1CNow® Produktfamilie von Bayer Diabetes Care erworben. Das A1CNow+® Multitest A1C System und das A1CNow® SELFCHECK At-Home A1C System sind wichtige Testgeräte für die einfache Überwachung des A1C Wertes. Die Tests stellen Gesundheitseinrichtungen und Menschen mit Diabetes Angaben über die Kontrollen des durchschnittlichen Blutzuckers in den vergangenen ca. 3 Monaten zur Verfügung.

(Logo: http://photos.prnewswire.com/prnh/20130710/DE43031LOGO )

„Wir sind über die Aufnahme des A1CNow Systems in das Produktportfolio von PTS stolz", sagt Robert Huffstodt, President und CEO von PTS, Inc. „Es gibt einen nachgewiesenen Zusammenhang zwischen den A1C Werten, dem Lipidspiegel sowie der Gefahr von Komplikationen bei Diabetes, und die A1CNow Produkte sind wichtige Werkzeuge, die Gesundheitseinrichtungen und Patienten bei der Feststellung unterstützen, wie gut ihr Plan bei der Behandlung von Diabetes funktioniert."

Der Erwerb von A1CNow stärkt das Produktportfolio von PTS durch die Aufnahme von Testmöglichkeiten, die von zahlreichen derzeitigen PTS-Kunden bereits gefordert werden. Die schnelle Verfügbarkeit von Resultaten und die Mobilität des A1CNow Systems ermöglichen es den Gesundheitseinrichtungen, die Diabeteskontrolle mit den Patienten sofort zu besprechen und es ist optimal für den ambulanten Einsatz geeignet.

„Wir sehen diese Akquisition sowohl für PTS- als auch für A1CNow-Kunden als eine durchaus positive Entwicklung", erklärt Huffstodt.
'/>"/>

SOURCE Polymer Technology Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PTS, Inc. Acquires A1CNow and Expands Product Portfolio
2. Noser Engineering AG erweitert sein Medizintechnik-Portfolio im Hinblick weltweiter Regulierungsauflagen und verkürzt die Zeit bis zur Markteinführung
3. United BioSource Corp. erweitert mit entscheidender Neubesetzung Potenzial in Europa
4. Ansell erweitert antimikrobielles Produktangebot mit einem neuen latexfreien Operationshandschuh
5. Boston Healthcare erweitert Gesundheitsökonomie-, Preis- und Vergütungsberatung in Asien
6. Harvest Technologies Corporation erhält CE-Kennzeichnung für erweiterte klinische Indikation zur Behandlung nicht optionaler kritischer Extremitätenischämie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ ... Alliance (PPHA). The PPHA's passion for others' well-being and ... greats, treated for obstructive sleep apnea (OSA) has propelled them ... in the valley. The most recent plans for an event ...
(Date:1/22/2015)... a famous wedding dress company offering many trendy designs. Today, ... Twitter, and Pinterest. The fans will have an opportunity to ... week. , Moreover, the company has extended its 2015 New ... for more information. , Angelweddingdress is a famous ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... significant bone mass in the first year after the transplant, ... bodies from rejecting the new organ. The bone loss greatly ... fractures among this group ranges from 22 percent to 44 ... but which drugs work best in this situation is unclear. ...
... suggest that kids who struggle to breathe during sleep ... out. ,Adenotonsillectomy is a common surgical procedure in ... performed to treat recurring bouts of tonsillitis. During the ... to treat obstructive sleep apnea (OSA), a condition in ...
... 34 years old. Advances in chemotherapy and radiotherapy have ... cancer, but since men who get the disease are ... and its treatment on fertility remains. ,While ... found fertility rates unchanged. These conflicting results suggested the ...
... has shown that a chemotherapy regimen combining vinorelbine (Navelbine) ... in the treatment of hormone-refractory prostate cancer . Specialists ... earlier in their disease. , However researchers ... treatment regimen is planned. From a group of 66 ...
... failure is a chronic but deadly condition caused by the ... weaker and weaker. An estimated 5 million Americans ... five years. It can be caused by high blood pressure, ... In a recent study it was seen that heart failure ...
... Previous studies show conflicting results over whether hormone replacement ... A recent study examines the pros and cons of ... combined HRT therapy for five years. All the women ... had menopausal symptoms, while others did not.Results show women ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
Medicine Products: